LakeShore Biopharma Co., Ltd.

corporate_fare Company Profile

LakeShore Biopharma Co., Ltd.

LSBCF·OTC·Life Sciences·CIK 0001946399

LakeShore Biopharma Co., Ltd. is a biopharmaceutical company that discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics. The company focuses on infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine that is currently marketed. Other products in development include PIKA, a rabies vaccine in Phase I/III and preclinical trials for rabies virus, and PIKA YS-ON-001, an immuno-oncology therapeutic candidate in Phase I trials for pancreatic and hepatocellular cancer. The pipeline also features PIKA YS-HBV-001, a hepatitis B vaccine in Phase I trials, and PIKA YS-HBV-002, an immune-therapy vaccine in preclinical trials for chronic HBV infection. Additionally, PIKA YS-ON-001 and PIKA Influenza Vaccine are in preclinical trials. The company was founded in 1994 as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd. in May 2024. LakeShore Biopharma Co., Ltd. is based in Beijing, China.

LakeShore Biopharma Co., Ltd. (OTC:LSBCF) is a publicly traded company in the Life Sciences sector. Wiseek monitors LSBCF SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

LakeShore Biopharma Completes Going-Private Merger, Shares to Be Delisted (2026-06-24)
LakeShore Biopharma Completes Going-Private Transaction at $0.066 Per Share (2026-06-24)
LakeShore Biopharma Completes Going-Private Merger, Shareholders to Receive $0.066/Share (2026-06-24)
LakeShore Biopharma Shareholders Approve Go-Private Merger Agreement (2026-06-19)
LakeShore Biopharma Sets Shareholder Meeting to Vote on Going-Private Merger (2026-05-28)

Financial Snapshot

Fiscal year ended March 31, 2025

Revenue

¥614.96M CNY

Net Income

-¥99.98M CNY

Diluted EPS

-¥5.22 CNY

Op. Cash Flow

-¥120.98M CNY

Free Cash Flow

-¥133.69M CNY

Gross Profit

¥507.19M CNY

Operating Income

-¥86.29M CNY

Cash & Equivalents

¥28.08M CNY

Total Debt

¥413.94M CNY

Debt / Equity

0.83×

Net Margin

-16.3%

Shares Outstanding

20.77M sh

Source: 20-F · filed 2025-07-31 · accession 0001213900-25-069880

Insider Transactions

LSBCF files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with L →

show_chartPrice Chart

Loading chart...

feed LSBCF - Latest Insights

Filing Type

Date Range

LSBCF

Jun 24, 2026, 12:16 PM EDT

Filing Type: SC 13E3/A

Importance Score:

LakeShore Biopharma Completes Going-Private Merger, Shares to Be Delisted

Price at Filing: $0.067

Real-time Price: $0.067

Change: Low Volume

Market Cap: $2.761M

Sentiment: Negative

View Wiseek Article

LSBCF

Jun 24, 2026, 12:15 PM EDT

Filing Type: 6-K

Importance Score:

LakeShore Biopharma Completes Going-Private Transaction at $0.066 Per Share

Price at Filing: $0.067

Real-time Price: $0.067

Change: Low Volume

Market Cap: $2.761M

Sentiment: Negative

View Wiseek Article

LSBCF

Jun 24, 2026, 12:13 PM EDT

Source: EQS

Importance Score:

LakeShore Biopharma Completes Going-Private Merger, Shareholders to Receive $0.066/Share

Price at Filing: $0.067

Real-time Price: $0.067

Change: Low Volume

Market Cap: $2.761M

Sentiment: Neutral

View Wiseek Article

LSBCF

Jun 19, 2026, 8:05 AM EDT

Source: EQS

Importance Score:

LakeShore Biopharma Shareholders Approve Go-Private Merger Agreement

Price at Filing: $0.067

Real-time Price: $0.067

Change: Low Volume

Market Cap: $2.761M

Sentiment: Neutral

View Wiseek Article

LSBCF

May 28, 2026, 9:25 AM EDT

Filing Type: 6-K

Importance Score:

LakeShore Biopharma Sets Shareholder Meeting to Vote on Going-Private Merger

Price at Filing: $0.0993

Real-time Price: $0.067

Change: Low Volume

Market Cap: $2.761M

Sentiment: Negative

View Wiseek Article

LSBCF

May 28, 2026, 8:41 AM EDT

Filing Type: SC 13E3/A

Importance Score:

Definitive Proxy Filed for Going-Private Merger at $0.066/Share; Shareholder Vote Set for June 19

Price at Filing: $0.0993

Real-time Price: $0.067

Change: Low Volume

Market Cap: $2.761M

Sentiment: Negative

View Wiseek Article

LSBCF

May 08, 2026, 9:10 AM EDT

Filing Type: SC 13E3/A

Importance Score:

LakeShore Biopharma Finalizes Going-Private Terms at Drastically Reduced Price of $0.066 Per Share Amid Massive Liabilities

Price at Filing: $0.037

Real-time Price: $0.067

Change: Low Volume

Market Cap: $2.761M

Sentiment: Negative

View Wiseek Article

LSBCF

Apr 29, 2026, 9:08 AM EDT

Filing Type: SCHEDULE 13D/A

Importance Score:

Going-Private Merger Consideration Drastically Cut by 92.7% to $0.066 Per Share

Price at Filing: $0.0278

Real-time Price: $0.067

Change: Low Volume

Market Cap: $2.761M

Sentiment: Negative

View Wiseek Article

LSBCF

Apr 29, 2026, 8:12 AM EDT

Filing Type: 6-K

Importance Score:

LakeShore Biopharma Amends Go-Private Deal, Cuts Shareholder Payout by 92%

Price at Filing: $0.0278

Real-time Price: $0.067

Change: Low Volume

Market Cap: $2.761M

Sentiment: Negative

View Wiseek Article

LSBCF

Apr 29, 2026, 8:03 AM EDT

Source: EQS

Importance Score:

LakeShore Biopharma Slashes Going-Private Offer Price to $0.066 Per Share, Down From $0.90

Price at Filing: $0.0278

Real-time Price: $0.067

Change: Low Volume

Market Cap: $2.761M

Sentiment: Negative

View Wiseek Article

LSBCF

Mar 25, 2026, 8:00 AM EDT

Source: Dow Jones Newswires

Importance Score:

LakeShore Biopharma Receives Revised Non-Binding Acquisition Proposal

Price at Filing: $0.045

Real-time Price: $0.067

Change: Low Volume

Market Cap: $2.761M

Sentiment: Positive

View Wiseek Article

corporate_fare Company Profile